We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Equillium Inc is a biotechnology developing therapies to treat autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with... Equillium Inc is a biotechnology developing therapies to treat autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph 2 ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease. Show more
Equillium retains rights to itolizumab following substantial funding from Ono partnership Evaluating accelerating Phase 3 EQUATOR study in aGVHD to completion in Q1 2025 Phase 2 ulcerative...
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory...
Dual and synergistic signaling of IL-15 and IL-21 robustly augments NK and CD8 T cell responses Highlights importance of dual inhibition or activation for therapeutic approaches Equillium Inc...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.1078 | 16.7755991285 | 0.6426 | 0.8 | 0.64 | 126751 | 0.73710537 | CS |
4 | 0.0804 | 12 | 0.67 | 0.8 | 0.5605 | 137631 | 0.67581355 | CS |
12 | -0.1784 | -19.2075796727 | 0.9288 | 1.5 | 0.5605 | 187812 | 0.87091975 | CS |
26 | 0.0794 | 11.8330849478 | 0.671 | 1.5 | 0.5605 | 154041 | 0.87544545 | CS |
52 | 0.0044 | 0.58981233244 | 0.746 | 3.25 | 0.5605 | 250997 | 1.32188544 | CS |
156 | -3.0496 | -80.2526315789 | 3.8 | 4.3799 | 0.45 | 167643 | 1.3426677 | CS |
260 | -3.3196 | -81.5626535627 | 4.07 | 30.2 | 0.45 | 362200 | 10.57354794 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions